Related Experiment Video
Updated: May 17, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
c-Met in pancreatic cancer stem cells: therapeutic implications
Marta Herreros-Villanueva1, Aizpea Zubia-Olascoaga, Luis Bujanda
1Division of Oncology Research, Department of Medicine, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Pancreatic cancer is the deadliest solid cancer and currently the fourth most frequent cause of cancer-related deaths. Emerging evidence suggests that cancer stem cells (CSCs) play a crucial role in the development and progression of this disease. The identification of CSC markers could lead to the development of new therapeutic targets. In this study, the authors explore the functional role of c-Met in pancreatic CSCs, by analyzing self-renewal with sphere assays and tumorigenicity capacity in NOD SCID mice. They concluded that c-Met is a novel marker for identifying pancreatic CSCs and c-Met(high) in a higher tumorigenic cancer cell population. Inhibition of c-Met with XL184 blocks self-renewal capacity in pancreatic CSCs. In pancreatic tumors established in NOD SCID mice, c-Met inhibition slowed tumor growth and reduced the population of CSCs, along with preventing the development of metastases.
Insights
This study identifies c-Met as a novel marker for pancreatic cancer stem cells (CSCs). Inhibiting c-Met reduces CSC self-renewal, slows tumor growth, and prevents metastasis in preclinical models.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Medicine
Background:
- Pancreatic cancer is a leading cause of cancer death.
- Cancer stem cells (CSCs) are implicated in pancreatic cancer development and progression.
- Identifying CSC markers is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the functional role of c-Met in pancreatic CSCs.
- To determine if c-Met can serve as a marker for pancreatic CSCs.
- To evaluate the therapeutic potential of targeting c-Met in pancreatic cancer.
Main Methods:
- Sphere assays were used to analyze CSC self-renewal capacity.
- Tumorigenicity was assessed in NOD SCID mice.
- The effect of c-Met inhibition using XL184 on CSCs and tumor growth was evaluated.
Main Results:
- c-Met was identified as a novel marker for pancreatic CSCs.
- High c-Met expression correlated with increased tumorigenic potential.
- XL184 treatment inhibited pancreatic CSC self-renewal.
- Inhibition of c-Met slowed tumor growth and reduced CSC populations in vivo.
- c-Met inhibition also prevented the development of metastases.
Conclusions:
- c-Met is a promising novel marker for identifying and targeting pancreatic CSCs.
- Targeting c-Met represents a potential therapeutic strategy to combat pancreatic cancer progression and metastasis.
Related Concept Videos
01:19Mesenchymal Stem Cells
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...